Apr. 17, 2025 — A professor's casual hike in the High Sierra turned into a new elevation record for California's highest tree, the Jeffrey pine, which wasn't formerly known to grow at extreme ...

SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors.

A clinical trial co-led by the Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug ...

NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for ...

Among patients with inflammatory bowel disease (IBD), overlapping biologic therapy was common during medication switches and was not associated with a higher risk for infection than nonoverlapping ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those with prior biologic use, positioning it as a potential first-line ...